Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

The article is available online at http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007-0 6- 095646v1. The analysis will also be published in a future print edition of Blood.

About PNH

PNH is an acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH is a rare disease that affects an estimated 8,000 to 10,000 people in North America and Europe.(13) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(3) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger.(2) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(4) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(13,4)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS).(14,15,16,17) In patients with thrombosis of unknown origin, PNH may be an underlying cause.(2,18)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk.(2,18)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commi
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Showed Significantly Improved Functioning Within Three ... ... Nearly half of patients,with schizophrenia fail to remain on their medication ... from a new international,study showed that patients treated with risperidone long-acting ...
... Phase III Clinical Trial of Acetavance(TM) for the Treatment of ... ... Trial of Omigard(TM) Completes Patient Enrollment, SAN DIEGO, May ... company focused on in-licensing,developing and commercializing proprietary product candidates principally,for ...
Cached Medicine Technology:Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 2Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 3Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 4Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 5Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 7Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 8Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 9
(Date:7/10/2014)... -- Most professional football players who have shoulder stabilization ... new study finds. Shoulder instability is a common ... after surgery to fix the problem has been unclear, ... 60 players who had shoulder stabilization surgery. Ninety percent ... play, defined as playing in at least one regular ...
(Date:7/10/2014)... who have a vasectomy may be at increased risk ... But the risk is comparatively small, the researchers acknowledged. ... more research is needed to determine if the study ... researchers analyzed data from more than 49,400 American men ... During that time, 6,023 cases of prostate cancer were ...
(Date:7/10/2014)... better prepared to respond to an active shooter incident ... study in the journal Prehospital and Disaster Medicine ... the EMS provider comfort level with respect to entering ... neutralized or working with law enforcement personnel during that ... shooting, the Virginia Tech campus shooting, the 2009 Fort ...
(Date:7/10/2014)... health concerns in the United States, with 32 percent ... 2012. As health problems such as childhood obesity grow, ... the problem. , A new study, led by Jenine ... at Washington University in St. Louis, examined the use ... conversations about the issue of overweight kids. , The ...
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) patients ... of life. Some patients have disturbed sleep/wake patterns ... while other patients may be subject to sudden ... PD patients may exhibit REM-sleep behavior disorder (RBD), ... even before motor symptoms appear. A review in ...
Breaking Medicine News(10 mins):Health News:Shoulder Surgery Gets NFL Players Back in the Game 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2
... is a serious complication that can occur in children ... lead to heart attack, pulmonary embolism and other cardiovascular ... research performed in Italy by the Laboratory of Genetic ... Catholic University in collaboration with the Haematology Division of ...
... Philadelphia have discovered a second gene that causes Alagille ... affects many organs.// , This finding may have ... Children's Hospital team had earlier discovered the first gene ... that mutations in the NOTCH 2 gene were linked ...
... solid food to infants less than six months old is ... food allergies later and new moms should rather breastfeed them ... be avoided for the first six months, and certain items ... introduced until even later, according to the American College of ...
... Danish residents revealed that a specific mutation in the CHEK2 ... cancer in her lifetime. The study, which was the first ... cancer risk associated with it, in the general population, will ... of Clinical Oncology. ,"Our study shows that ...
... compounds in cocoa could improve blood circulation, according ... flow// in menopausal women with high cholesterol.,'The totality ... new insights into how cocoa flavanols may improve ... known,' said Harold Schmitz, PhD, Chief Science Officer ...
... the University of Georgia have suggested that cross-immunity created ... strain protect against infection //,by related serotypes thus leading ... This finding would help understand the pattern of ... since about the mid 1980s, there's been a sequential ...
Cached Medicine News:Health News:Thrombosis, a Serious Risk in Children with Leukemia 2Health News:Second Alagille Syndrome Gene discovered: More information on kidney disease 2Health News:CHEK 2 Gene Mutation Triples Breast Cancer Risk 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 2Health News:Waxing And Waning Of Dengue Epidemics Attributed To Cross-Immunity 3
Premium Full Color Digital Ultrasound...
... The new ACUSON CV70 cardiovascular ultrasound ... capabilities in a powerful, all-digital ultrasound ... sensitivity, color flow sensitivity and spatial ... the ACUSON family of cardiovascular products. ...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m...
AngioSpeed V series, it is an Angiography system designed for vascular treatment in various radiological regions, cardiology, and neurology. SHIMADZU brings you a single system with all units fused t...
Medicine Products: